ADA: Victoza's 'Broad' CV Benefit Leads The Way For Semaglutide
Full cardiovascular (CV) outcomes data for Novo Nordisk AS's leading diabetes therapy, Victoza (liraglutide), show positive effects across a wide range of CV endpoints – placing the company in a strong position with the first GLP-1 product and second ever diabetes therapy to show a benefit on CV mortality.
You may also be interested in...
Pfizer, Merck KGaA, Novo Nordisk, Shire, Allergan and Teva are among those pharmaceutical majors still to report their 2Q results. Scrip considers what’s in store.
Novo Nordisk's executive vice president and chief scientific officer, Dr. Mads Krogsgaard Thomsen, talks to Scrip about the Danish firm's biggest challenges as a leader in the development of diabetes therapies – including the positioning of its numerous marketed type 2 diabetes therapies and how the company can stay innovative in a saturated disease space.
Last week was another losing week in broad stock markets, driven by fears of a Brexit. The S&P 500 index was depressed by about 1% and in what is becoming an unwelcome recent trend, the NASDAQ Biotech index (NBI) underperformed the broad stock market by finishing the week down over 4%. While some of this underperformance can be attributed to risk-aversion at a time of short-term macroeconomic uncertainty, missed expectations in life science companies did not help matters.